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A prospective comparison of three argatroban treatment regi-
mens during hemodialysis in end-stage renal disease.
Background. We prospectively evaluated 3 treatment regi-
mens of argatroban, a direct thrombin inhibitor, for providing
adequate, safe anticoagulation in patients with end-stage renal
disease (ESRD) during hemodialysis.
Methods. In this randomized, 3-way crossover study, ESRD
patients underwent hemodialysis sessions of 3- or 4-hour du-
ration using high-flux membranes and each of 3 argatroban
treatment regimens (A: 250-lg/kg bolus, with an additional 250-
lg/kg bolus allowed; B: 250-lg/kg bolus followed by 2-lg/kg/min
infusion; C: steady-state, 2-lg/kg/min infusion initiated 4 hours
before dialysis). Pharmacodynamic effects including activated
clotting times (ACTs); hemodialysis efficacy including single-
pool Kt/V, urea reduction ratio (URR), and circuit flow; and
safety through a 3-day follow-up were monitored. Argatroban
pharmacokinetic parameters including dialytic clearance were
evaluated during regimen C.
Results. Thirteen patients completed 38 hemodialysis sessions
(1 patient withdrew consent after 2 sessions). Mean ± SD ACTs
increased from 131 ± 14 seconds at baseline to 153 ± 24, 200 ±
30, and 197 ± 33 seconds, respectively, after 60 minutes of
hemodialysis using regimens A, B, and C. Across regimens,
mean Kt/Vs (1.5–1.6) and URRs (70%-73%) were comparable.
No dialyzer was changed; 1 session was shortened 15 minutes
because of circuit clot formation. Systemic argatroban clear-
ance increased ∼20% during hemodialysis, without clinically
significantly affecting ACTs. Upon argatroban discontinuation,
ACTs and plasma argatroban decreased concurrently (elimi-
nation half-life, 35 ± 6 min). No thrombosis, bleeding, serious
adverse events, or clinically significant changes in vital signs or
routine laboratory measures occurred.
Conclusion. Argatroban, administered by each treatment
regimen, provides safe, adequate anticoagulation to enable suc-
cessful hemodialysis in ESRD patients. Argatroban dialytic
clearance by high-flux membranes is clinically insignificant.
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Anticoagulation is generally required for effective
hemodialysis, and unfractionated heparin is most com-
monly used for this purpose. However, there are lim-
itations associated with heparin, including dependence
on adequate antithrombin levels, unpredictable antico-
agulant effects, no inhibition of clot-bound thrombin,
and heparin-induced thrombocytopenia (HIT), which is
an immune-mediated, prothrombotic reaction to hep-
arin [1]. Antibodies that cause HIT have been detected
in up to 12% of patients with end-stage renal disease
(ESRD) receiving chronic dialysis [2]. Adverse effects
commonly make some alternative anticoagulant options
impractical during hemodialysis, such as metabolic and
hemodynamic complications with citrate [3], bleeding
complications with warfarin [4], and cross-reactivity
with HIT antibody with low-molecular-weight heparin
and danaparoid [5]. Although used successfully during
hemodialysis in some patients, hirudins such as lepirudin,
which directly inhibit thrombin, are predominantly re-
nally cleared and associated with an increased elimi-
nation half-life and bleeding risk in renal failure, fre-
quent formation of antihirudin antibodies that may alter
the agent’s pharmacokinetics, poor correlation between
plasma drug concentrations and the level of anticoagula-
tion assessed by the activated partial thromboplastin time
(aPTT), differences in drug filtration characteristics ac-
cording to the type of dialyzer used, and possible allergic
or anaphylactoid reactions [6, 7].
Argatroban is a rapidly acting, direct thrombin in-
hibitor that effectively inhibits free and clot-bound
thrombin without need of a cofactor [8], has predictable
anticoagulant effects [9, 10], and does not induce or
potentiate HIT [11]. Unlike hirudins, argatroban is
hepatically metabolized [10], is not associated with for-
mation of antibodies to itself [12], and its pharmacokinet-
ics and pharmacodynamics are not significantly affected
by renal dysfunction [10]. Prospective data on arga-
troban anticoagulation during hemodialysis are limited,
mainly including Japanese case reports or small studies
in patients with antithrombin deficiency [13, 14] or HIT
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[15–17]. However, these data consistently indicate that
argatroban may be used successfully during dialysis and,
hence, suggest that an optimal protocol for its use during
high-flux hemodialysis should be developed. Potential di-
alytic removal of argatroban by high-flux membranes has
not yet been precisely estimated.
We report a prospective, randomized, crossover study
conducted to establish the adequacy of anticoagulation
and safety of 3 treatment regimens of argatroban in pa-
tients with ESRD during high-flux hemodialysis. We also
investigated the pharmacokinetics of argatroban in this
setting, including its dialytic clearance.
METHODS
This prospective, randomized, open-label, 3-way
crossover, 2-center, pharmacokinetic-pharmacodynamic
study characterized and compared the safety and effects
of 3 treatment regimens of argatroban in patients with
ESRD undergoing maintenance hemodialysis. The insti-
tutional review board at each center approved the study.
Subjects gave informed consent. A sufficient number of
patients was to be enrolled so that 12 patients completed
the study.
Patients and treatment
Patients between 21 and 75 years in age with ESRD on
maintenance hemodialysis for at least 3 months were eli-
gible. All patients had a urine output <100 mL/day, Kt/V
≥1.2 within the previous month, an estimated dry weight
within 30% of ideal body weight, and were able to achieve
dialysis blood flow rates ≥300 mL/min, and to tolerate
a study session of up to 9 hours. Females of childbear-
ing potential were required to use medically approved
methods of birth control for 7 days before the study and
throughout the study. Patients were excluded if they had
any clinically relevant abnormality (other than ESRD);
uncontrolled cardiovascular, hematologic, respiratory,
central nervous system, or gastrointestinal disease; sig-
nificant hepatic insufficiency (defined as total bilirubin
>1.5 mg/dL or transaminase elevations >2 times the up-
per limit of normal); history of bleeding diathesis, drug
allergy of clinical significance, regular alcohol consump-
tion, or chronic alcoholism; surgery or significant physi-
cal trauma within the past 3 months; systolic blood pres-
sure >180 mm Hg or diastolic blood pressure >100 mm
Hg, unless the investigator felt this would not endan-
ger the subject during the study; morbid obesity; usage
of warfarin, other anticoagulants, or nonsteroidal anti-
inflammatory drugs except aspirin currently, or of pheny-
toin, cimetidine, rifampin, cyclosporine, or tacrolimus
within the past month; or serum albumin <2.5 g/dL, ac-
tivated clotting time (ACT) >200 seconds, prothrom-
bin time (PT) >16 seconds, international normalized ra-
tio (INR) >1.4, an unexplained aPTT >2 times the up-
per limit of normal, hematocrit <30%, or hemoglobin
<8 g/dL. Patients were also excluded if they had been
treated with an investigational drug within the past
month, previously randomized into the study, donated
>500 mL blood within the past 56 days, or were >3 kg
above their estimated dry weight.
Patients were assigned in the order of their en-
rollment to an argatroban treatment sequence accord-
ing to a randomized schedule. Patients underwent 3
hemodialysis sessions, each 3 to 4 hours in duration
and separated by >48 hours, using high flux CT 190
dialyzer membranes (Baxter, Deerfield, IL, USA) and
argatroban (GlaxoSmithKline, Philadelphia, PA, USA)
anticoagulation. Ultrafiltration was set to reach the pa-
tient’s current estimated dry weight. The argatroban
treatment regimens were designed to achieve ACTs
>180% of baseline (i.e., predosing) during most of the
hemodialysis session, and >140% of baseline at the end
of the session. In regimen A, patients received a 250-lg/kg
bolus at the start of the hemodialysis session and, at the
investigator’s discretion, an additional 250-lg/kg bolus af-
ter 2 hours if the ACT was <140% of baseline. In regimen
B, patients received a 250-lg/kg bolus at the start of the
hemodialysis session, followed by continuous infusion of
2 lg/kg/min. The infusion was discontinued 1 hour before
the end of the session. In regimen C, a continuous infusion
of 2 lg/kg/min was started 4 hours before hemodialysis to
allow achievement of steady-state concentrations before
initiation of hemodialysis. The infusion was maintained
during hemodialysis, and discontinued at the termination
of hemodialysis. Dose titration up to 5 lg/kg/min was per-
mitted if desired to achieve adequate anticoagulation.
Treatment was not permitted if the baseline ACT ex-
ceeded 200 seconds. Argatroban was discontinued if the
ACT was >400 seconds for 2 consecutive hours, or if any
clinically significant bleeding event occurred.
Assessments
Pharmacodynamics. In each hemodialysis session,
the whole blood HemoTec (Medtronic, Englewood, CO,
USA) ACT, plasma aPTT, and plasma PT/INR were mea-
sured before argatroban was administered; at 15, 30, 60,
120, and 180 minutes after the start of hemodialysis; at the
end of hemodialysis (for sessions that lasted longer than
180 min); and at 15 (regimens B and C), 30 (regimens B
and C), and 60 minutes after the end of hemodialysis. For
regimen C treatment, coagulation assessments were also
made 210 and 240 minutes after starting argatroban (i.e.,
at −30 and 0 minutes, respectively, before hemodialysis).
Pharmacokinetics. During regimen C treatment,
plasma samples for pharmacokinetic analysis were ob-
tained at the same times that pharmacodynamic spec-
imens were obtained. Dialyzer effluent was collected
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before the start of dialysis and quantitatively for suc-
cessive 1-hour periods during dialysis. The total vol-
ume of each hourly collection was recorded, and 20 mL
aliquots were retained for argatroban analysis. Samples
were stored at −70◦C until assayed.
Hemodialysis efficacy. All circuits were visually in-
spected for blood flow and evidence of clot formation dur-
ing hemodialysis. Serum blood urea nitrogen (BUN) was
assessed 5 minutes before hemodialysis, and at the com-
pletion of hemodialysis. Hemodialysis efficacy was as-
sessed for each treatment session by means of the single-
pool Kt/V, calculated using the Daugirdas formula [18],
and the urea reduction ratio (URR), calculated as the
change in BUN between the start and end of hemodialy-
sis, divided by the BUN at the start of hemodialysis. Dur-
ing each treatment session, arterial and venous pressures
were measured 15, 30, 60, 120, and 180 minutes after the
start of hemodialysis, and at the end of hemodialysis. Di-
alyzer fiber bundle volumes were measured during each
regimen at one center according to the unit’s protocol us-
ing a Renatron II dialyzer reprocessing system with Re-
nalin solution (Minntech Corporation, Minneapolis, MN,
USA).
Safety. Patients underwent physical exams 7 days be-
fore the first hemodialysis session, and 3 days after the
final session, and sitting blood pressure and heart rate,
routine clinical laboratory tests (albumin, alkaline phos-
phatase, total bilirubin, BUN, creatinine, calcium, choles-
terol, chloride, glucose, lactate dehydrogenase, potas-
sium, total protein, sodium, transaminases, triglycerides,
uric acid, CO2, hemoglobin, hematocrit, platelets, red
blood cells, white blood cells, neutrophils, lymphocytes,
monocytes, eosinophils, and basophils), and stool guiac
were assessed. Vital signs were also monitored during
and after hemodialysis when pharmacodynamic assess-
ments were done. Adverse events were assessed during
hemodialysis and at 3-day follow-up.
Analyses
Pharmacodynamics, hemodialysis efficacy, and safety.
Pharmacodynamic, hemodialysis efficacy, and safety data
were summarized by treatment regimen (and overall for
safety), and descriptive statistics were computed. The fre-
quency of ACTs >180% or >140% of baseline values was
determined for each assessment time during hemodialy-
sis. For pharmacodynamic and safety data, percentage
changes in responses from the baseline value were com-
pared with a change of “0” using the signed rank test
(significance level of 0.05). Single-pool Kt/V and URR
values were compared between treatment regimens us-
ing the analysis of variance (ANOVA) with Bonferroni
test (Graphpad Instat program, version 3.05, San Diego,
CA, USA).
Pharmacokinetics. Plasma and dialysate concentra-
tions of argatroban during regimen C treatment were
measured using liquid chromatography/tandem mass
spectrometry [19] at the Worldwide Bioanalysis Depart-
ment, GlaxoSmithKline, King of Prussia, PA, USA. The
argatroban concentration-time profile for each patient
was analyzed using Winnonlin version 4.0.1 (Pharsight
Corporation, Mountain View, CA, USA). Systemic arga-
troban clearance (CL) before and during hemodialysis
was calculated as the argatroban infusion rate divided by
the steady-state plasma concentration. Dialytic clearance
was determined using the dialysate recovery method and
calculated as the ratio Ahd/AUChd, where Ahd was the
total recovery of argatroban in dialyzer effluent during
hemodialysis (determined by summation of individual re-
coveries during the successive 1-hour collection periods),
and where AUChd was the area under the plasma
concentration-versus-time curve during hemodialysis.
The elimination half-life (t 1
2
) was determined by analysis
of declining argatroban concentrations following cessa-
tion of infusion. The elimination rate constant (ke) was
calculated as 0.693/t 1
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The study population included 13 patients with ESRD
who completed a total of 38 hemodialysis sessions using
argatroban anticoagulation administered as a 250-lg/kg
bolus (regimen A), 250-lg/kg bolus plus 2-lg/kg/min infu-
sion (regimen B), or steady-state infusion of 2 lg/kg/min
(regimen C). Twelve patients completed the study. One
patient completed sessions using regimens A and B, but
withdrew consent during the regimen C session; data
from this patient were included in the pharmacodynamic
and efficacy analyses for regimens A and B and in all
safety analyses.
The population was predominantly male (N = 9) and
African American (N = 11; 2 Caucasian patients), with
a mean (SD) age of 54 (12) years. Their mean baseline
systolic and diastolic blood pressures were 139 (21) and
86 (12) mm Hg, respectively. Their chronic renal failure
arose secondary to hypertension (N = 8), diabetes mel-
litus and hypertension (N = 3), or polycystic kidney dis-
ease (N = 2). Vascular access was provided by a tunneled
catheter (N = 5), arteriovenous fistulas (N = 6), or arteri-
ovenous graft (N = 2). Seven patients took aspirin daily.
At study entry, coagulation measures included a mean
(SD) ACT of 131 (14) seconds, aPTT of 43 (12) seconds,
and INR of 1.1 (0.1).
Hemodialysis in each session lasted for 4 hours (N =
8), 3.5 hours (N = 2; 1 of whom had 1 session shortened by
15 min), or 3 hours (N = 3). Eleven (85%) of 13 patients
received a second bolus at a mean (SD) 125 (14) minutes
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Fig. 1. ACTs in ESRD patients undergoing hemodialysis using argatroban anticoagulation. Argatroban was administered as a bolus (regimen A;
A), bolus plus infusion (regimen B; B), or steady-state infusion (regimen C; C). Summarized responses are compared by regimen in (D) (regimen
A, diamonds; regimen B, squares, regimen C, triangles). Data obtained at the end of hemodialysis and 15, 30, and 60 minutes after the end of
hemodialysis are presented, respectively, at 222 minutes (the mean duration of the hemodialysis sessions), and 237, 252, and 282 minutes after the
start of hemodialysis. For patients whose sessions lasted 3 hours (N = 3), data obtained 180 minutes after the start of hemodialysis are shown with
the “end of hemodialysis” results. For figure clarity purposes only, regimen C’s predose mean (SD) ACT of 132 (25) seconds is not shown in (D).
after regimen A treatment was initiated. During regimen
C treatment, the infusion dose remained 2 lg/kg/min in
all but 1 patient, whose dose was adjusted to 3 lg/kg/min
after 22 minutes of hemodialysis. Patients received mean
(SD) total argatroban doses of 461 (94) lg/kg during reg-
imen A, 573 (52) lg/kg during regimen B, and 912 (143)
lg/kg during regimen C.
Pharmacodynamics
For each regimen, argatroban therapy produced gener-
ally similar temporal response profiles during hemodial-
ysis for ACTs (Fig. 1), aPTTs (Fig. 2), and, although not
routinely used for monitoring parenteral anticoagulation,
INRs (data not shown). With the exception of the ACT
at 120 minutes and the end of hemodialysis during reg-
imen A treatment, all argatroban regimens significantly
prolonged these effect measures (relative to baseline) at
each assessment during hemodialysis. Peak responses oc-
curred at the first assessment (i.e., 15 minutes) after bolus
administration in regimens A and B. During much of the
treatment period, the level of anticoagulation was com-
parable between regimens B and C. At 60 minutes after
the start of hemodialysis, mean (SD) ACTs were 153 (24)
seconds in regimen A, 200 (30) seconds in regimen B, and
197 (33) seconds in regimen C; aPTTs in these respective
regimens were 66 (15), 91 (28), and 84 (23) seconds. When
argatroban was discontinued, coagulation measures be-
gan returning to baseline levels in each regimen. Within
an hour of the end of hemodialysis, mean (SD) ACTs in
regimens A, B, and C, respectively, were 141 (9), 134 (15),
and 154 (23) seconds.
ACTs >180% of baseline were relatively infrequent
during hemodialysis, occurring in no patient on regimen
A, 1 (8%) patient on regimen B, and 2 (17%) patients
on regimen C at 60 minutes after the start of hemodialy-
sis. By contrast, ACTs >140% of baseline occurred dur-
ing hemodialysis with each treatment regimen (Fig. 3).
This level of anticoagulation was more consistently
achieved when a continuous infusion (with or without
a bolus) was used. After 60 minutes of hemodialysis, ap-
proximately 70% of patients receiving regimens B or C,
compared with 8% patients receiving regimen A, had an
ACT >140% of baseline. With the exception of 2 patients
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Fig. 2. aPTTs in ESRD patients undergoing hemodialysis using argatroban anticoagulation. Data are presented as described in Figure 1. For figure
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Fig. 3. Frequency of ACTs >140% of baseline during hemodialysis.
Patients received argatroban as a bolus (regimen A; striped bars), bolus
plus infusion (regimen B, white bars), or steady-state infusion (regimen
C, black bars).
receiving regimen C, all patients, irrespective of treat-
ment regimen, had ACTs <140% of baseline within
60 minutes of completing hemodialysis.
Pharmacokinetics
The mean (SD) steady-state plasma argatroban con-
centration following 4 hours of continuous infusion at
Table 1. Argatroban pharmacokinetic parameters in ESRD patients
Mean (SD)
Parameter (N = 12)
Steady-state concentrationa ng/mL
240 minutes after infusion started 673 (176)
360 minutes after infusion startedb 605 (187)
Clearance mL/min/kg
Systemic, before hemodialysis 3.1 (0.9)
Systemic, during hemodialysis 3.4 (1.0)
Dialytic 0.7 (0.3)
Volume of distribution L/kg 0.15 (0.03)
Elimination rate constant, min−1 0.020 (0.003)
Elimination half-life minutes 35 (6)
aInfusion dose, 2 lg/kg/min.
bEquivalent to 120 minutes after start of hemodialysis.
2 lg/kg/min was 673 (176) ng/mL. Systemic clearance
was 3.1 (0.9) mL/min/kg before hemodialysis, and 3.4
(1.0) mL/min/kg during dialysis. Dialytic clearance of
argatroban measured by the recovery method was 0.7
(0.3) mL/min/kg, suggesting an increase of ∼20% in ar-
gatroban clearance by hemodialysis. Table 1 summarizes
these and other pharmacokinetic parameters of arga-
troban in ESRD patients, including a mean (SD) elim-
ination half-life of 35 (6) minutes.
Hemodialysis efficacy
Dialysis dose was effectively delivered using each arga-
troban treatment regimen, as evidenced by mean URRs
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Table 2. Hemodialysis efficacy with argatroban anticoagulation
Regimen A Regimen B Regimen C
Parameter (N = 13) (N = 13) (N = 12)
Urea reduction ratio % 73 (4) 72 (5) 70 (4)
mean (SD)a
Single-pool Kt/V, 1.5 (0.2) 1.6 (0.3) 1.5 (0.2)
mean (SD)a
Circuit inspection N
Fibrin strandsb 11 6 7
Dialyzer changed 0 0 0
Session shortened 0 1c 0
Regimen A: 250-lg/kg bolus, with additional 250-lg/kg bolus allowed; regimen
B: 250-lg/kg bolus plus 2-lg/kg/min infusion; regimen C: steady-state infusion of
2 lg/kg/min.
aP = 0.23 for urea reduction ratio, and P = 0.48 for Kt/V.
bAppearance of fibrin strands, early sludging, or early thrombus in the drip
bulb of the system; saline flushing was used to prevent further coagulation or
thrombus organization.
cA 3.5-hour session using regimen B was shortened by 15 minutes.
of 70% to 73% and single-pool Kt/V values of 1.5 to 1.6,
which were not different across the regimens (Table 2). In
4 patients with available data, pre- and postdialysis fiber
bundle volumes were not significantly different, with the
mean (SD) postdialysis values in regimens A, B, and C,
respectively, being 95% (1%), 97% (8%), and 96% (6%)
of the predialysis values.
No dialyzer was changed. Upon appearance of fib-
rin strands or early sludging in the dialysis system drip
bulb during regimens A (N = 11), B (N = 6), or C
(N = 7), saline flushing was used successfully to pre-
vent further coagulation or thrombus organization. One
(2.6%) of 38 hemodialysis sessions was shortened due
to circuit clot formation. This event occurred after 3.25
hours of hemodialysis (regimen B), and because only 15
minutes remained in the patient’s session, the dialyzer
was not changed. In this patient, ACT values during
hemodialysis using regimens A, B, and C, respectively,
were 122 to 228, 151 to 206, and 185 to 224 seconds,
and the infusion dose was adjusted to 3 lg/kg/min during
regimen C.
Safety
Adverse events were all mild or moderate in sever-
ity, and none occurred consistently across regimens or
was considered related to study drug (Table 3). The
only adverse events reported by more than 1 patient
were headache (N = 3, with 1 event during hemodial-
ysis in each of 2 patients and 1 event afterwards), pe-
ripheral edema (N = 3), pain (N = 2), and hypotension
(N = 2).
No patient died or experienced a thrombotic, hemor-
rhagic, or otherwise serious adverse event. There were no
clinically significant changes in heart rate, blood pressure,
or clinical laboratory values (excluding the ACT, aPTT,
PT/INR, and BUN) during the study.
DISCUSSION
Prevention of hemodialyzer clot formation and main-
tenance of vascular access patency are challenging prob-
lems in ESRD patients managed with hemodialysis.
Hemodialyzer clot formation may result in interrup-
tion or early termination of hemodialysis sessions, or in
subclinical loss of dialyzer fiber bundle volume, caus-
ing diminished dialysis delivery. Similarly, vascular ac-
cess thrombosis may impair or ultimately preclude per-
formance of hemodialysis. Chronic hemodialysis patients
are at risk for HIT, a hypercoagulable state triggered by
heparin. The antibodies that cause HIT have been de-
tected in up to approximately 1 in 8 ESRD patients [2].
The presence of these antibodies, even in the absence
of thrombocytopenia, has been associated with signifi-
cantly increased thrombotic morbidity in patients with
acute coronary syndrome [20, 21]. Although catastrophic
thrombotic events associated with HIT such as stroke,
peripheral occlusion with gangrene, and myocardial in-
farction [22, 23] are clinically obvious, more subtle events
including arteriovenous graft and hemodialyzer clot for-
mation may not be recognized as associated with heparin
treatment. Likewise, the platelet count in HIT may fall
more than 30% from baseline yet still be within the “nor-
mal” range, further obscuring the association. These con-
cerns, together with other known limitations of heparin
[1], has led to increasing interest in the use of alternative
anticoagulants in patients with ESRD, including those at
risk for HIT, during hemodialysis.
Direct thrombin inhibitors, including argatroban and
hirudins, represent an anticoagulant class distinct from
heparins. These agents exert their anticoagulant effects
by directly inhibiting thrombin-catalyzed or induced re-
actions without need of a cofactor. Direct thrombin in-
hibitors may be distinguished from one another in part on
the basis of their mode of elimination. The major route
of elimination of argatroban, unlike the hirudins, is hep-
atic metabolism, and not renal clearance. As such, ar-
gatroban may be a direct thrombin inhibitor of choice
in patients with renal impairment, including those with
ESRD who are dialysis dependent [6, 24]. There is no
specific antidote for direct thrombin inhibitors; however,
effect measures typically return to baseline within 4 to
6 hours of discontinuing argatroban therapy [9], and it
has been suggested that recombinant factor VIIa may be
a useful pharmacologic agent for reversing severe bleed-
ing [25]. Among its other uses, argatroban is approved as
an anticoagulant in the United States for prophylaxis or
treatment of thrombosis in HIT [22, 23] and in patients
with or at risk for HIT undergoing percutaneous coro-
nary interventions [26], and in Japan in nonlacunar stroke
[27], chronic arterial occlusion [28], and during hemodial-
ysis in patients with antithrombin deficiency [13, 14].
For prophylaxis or treatment of thrombosis in HIT, the
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Table 3. Adverse events
N with event (13 patients/regimen)
Total Total
Adverse event Regimen A Regimen B Regimen C 3-day Follow-up N (%) eventsa
Headache 1 0 2 0 2 (15.4) 3
Peripheral edema 0 1 2 0 2 (15.4) 3
Pain 1 1 0 0 2 (15.4) 2
Hypotension 0 1 1 0 2 (15.4) 2
Respiratory disorder 1 0 0 1 1 (7.7) 2
Back pain 1 0 0 0 1 (7.7) 1
Anorexia 0 0 1 0 1 (7.7) 1
Dyspepsia 0 0 1 0 1 (7.7) 1
Nausea 0 0 1 0 1 (7.7) 1
Vomiting 0 0 1 0 1 (7.7) 1
Myalgia 0 1 0 0 1 (7.7) 1
Dizziness 0 0 1 0 1 (7.7) 1
Cough increased 1 0 0 0 1 (7.7) 1
Rhinorrhea 1 0 0 0 1 (7.7) 1
Upper respiratory infection 0 0 1 0 1 (7.7) 1
Regimen A: 250-lg/kg bolus, with additional 250-lg/kg bolus allowed; regimen B: 250-lg/kg bolus plus 2-lg/kg/min infusion; regimen C: steady-state infusion of 2
lg/kg/min.
aAll were mild or moderate in severity, and deemed unlikely to be related or unrelated to drug.
recommended argatroban starting dose is 2 lg/kg/min
(reduced to 0.5 lg/kg/min in patients with hepatic im-
pairment), adjusted to a target aPTT of 1.5 to 3 times the
baseline value.
We conducted this prospective, randomized, crossover
study to establish the adequacy of anticoagulation and
safety of 3 treatment regimens of argatroban in 13 pa-
tients with ESRD during hemodialysis. We also aimed to
characterize the pharmacokinetic profile of argatroban in
this setting, and determine the extent and significance of
any dialytic argatroban removal. The argatroban treat-
ment regimens (250-lg/kg bolus, 250-lg/kg bolus fol-
lowed by 2-lg/kg/min infusion, or steady-state infusion
of 2 lg/kg/min) were designed to target ACTs >180% of
baseline values during most of the hemodialysis session.
However, such ACTs were infrequently attained and,
indeed, unnecessary for adequate anticoagulation with
argatroban during hemodialysis. Rather, ACTs >140%
of baseline were more common, particularly when the
treatment regimen included continuous infusion. Also,
with infusion treatment, aPTT values typically were ap-
proximately 2 times the baseline value. At the levels of
anticoagulation achieved using each of the treatment reg-
imens, argatroban therapy provided adequate, safe an-
ticoagulation to enable effective hemodialysis. Efficacy
of hemodialysis was demonstrated by the acceptable de-
livered dialysis doses and the high frequency of session
completions. There was some evidence that the treatment
regimens using continuous infusion, compared with bo-
lus only, were more efficacious at minimizing the appear-
ance of fibrin strands or sludging in the dialyzer circuit,
perhaps related to their achievement of generally higher
levels of anticoagulation. Safety was demonstrated by a
lack of thrombotic, hemorrhagic, serious, or drug-related
adverse events, as well as no clinically significant changes
in vital signs or routine laboratory values. The most com-
mon adverse events, which were headache and periph-
eral edema, are not unexpected in this setting. Further-
more, argatroban’s elimination half-life of approximately
40 minutes led to rapid normalization of coagulation pa-
rameters after therapy was discontinued. This half-live
value and other estimated pharmacokinetic parameters
in ESRD patients agreed closely with values reported
previously for healthy subjects and patients with severe
renal impairment [10, 19]. Additionally, our data indicate
that dialytic clearance of argatroban with high-flux mem-
branes, as determined by the dialysate recovery method,
is clinically insignificant (approximately 20%).
CONCLUSION
These results help provide practical guidance regarding
argatroban treatment strategies in patients undergoing
hemodialysis. For example, in hospitalized patients re-
ceiving a steady-state argatroban infusion of 2 lg/kg/min
for other needs (e.g., prophylaxis or treatment of throm-
bosis in HIT), and who require hemodialysis, the infu-
sion could simply be maintained during hemodialysis.
Although patients in our study did not have active HIT, it
is anticipated that this treatment approach would be ade-
quate in such patients. Our findings of a clinically insignif-
icant ∼20% increment in argatroban clearance, with no
evidence of loss of effect (i.e., stable intradialytic ACTs
and aPTTs), suggest no significant risk of dialytic arga-
troban removal precipitating thrombosis. Also, for most
outpatients requiring hemodialysis, or hospitalized pa-
tients not currently receiving argatroban, the preferable
argatroban treatment regimen for hemodialysis may be
a 250-lg/kg bolus followed by a 2-lg/kg/min infusion. If
desired, the infusion could be stopped up to an hour in
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advance of the anticipated completion of hemodialysis
session. In our study, this regimen, compared with bo-
lus treatment only, resulted in more consistent levels of
anticoagulation, less fibrin strand formation, and a 112-
lg/kg increase in the mean total dose. In a recent case
series of critically ill HIT patients with liver dysfunc-
tion and acute renal failure requiring continuous renal
replacement therapy, the steady-state argatroban dose
associated with aPTTs of 1.5 to 2.5 times baseline was
approximately 0.5 lg/kg/min [29]. Although our study ex-
cluded patients with significant hepatic insufficiency, we
recommend a generally similar reduction in argatroban
dose (and careful monitoring using the aPTT or ACT) for
hemodialysis of the subset of ESRD patients with comor-
bid hepatic impairment; this remains to be prospectively
evaluated. Overall, this treatment guidance should fur-
ther facilitate safe and effective hemodialysis using alter-
native anticoagulation with argatroban in ESRD patients.
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